WAVE Clinical Platform vs EndoTool SubQ

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

WAVE Clinical Platform

by Excel Medical Electronics

EndoTool SubQ

by MONARCH MEDICAL TECHNOLOGIES

AI Verdict

While both are FDA-cleared AI-driven clinical decision support tools, they address distinct clinical challenges. Tool A, WAVE Clinical Platform, is a broad patient surveillance system focused on predicting general patient deterioration across various physiological parameters. In contrast, Tool B, EndoTool SubQ, is a highly specialized solution for optimizing subcutaneous insulin administration and managing individual patient responses to insulin.

Choose WAVE Clinical Platform if…

Choose WAVE Clinical Platform if your hospital requires an advanced, FDA-cleared AI-driven system for continuous patient surveillance and early warning of deterioration. This tool is ideal for proactively identifying at-risk patients up to six hours in advance, enabling timely clinical interventions and enhancing overall patient safety across multiple care settings.

View WAVE Clinical Platform →

Choose EndoTool SubQ if…

Choose EndoTool SubQ if your organization prioritizes precise, patient-specific clinical decision support for subcutaneous insulin management across all patient types, including pediatrics. This solution is best suited for improving glycemic control, reducing correctional dosing, and preventing hypoglycemia by dynamically adjusting to each patient's unique physiological response to insulin.

View EndoTool SubQ →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	WAVE Clinical Platform	EndoTool SubQ
Pricing	Contact for pricing	Contact vendor
Deployment	Software platform, leverages existing hospital IT infrastructure, client-server architecture, web-enabled devices.	Cloud-based (browser-based) and potentially thick client options.
FDA Status	1 AI-estimated	1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

WAVE Clinical Platform

WAVE Clinical Platform emphasizes an 'effortlessly' user-friendly experience and offers mobile device compatibility for alerts and data display, crucial for clinicians on the go. Its design allows for effective trending and viewing of patient data across various devices and EMRs, enhancing workflow efficiency.

Clinical Value

WAVE Clinical Platform

Both tools offer significant clinical value in their respective domains. However, WAVE Clinical Platform, as the 'first FDA-cleared AI patient surveillance system,' provides early warning of patient deterioration up to six hours in advance and has demonstrated a reduction in unexpected deaths to zero in a UPMC control group using its Visensia Safety Index. EndoTool SubQ shows strong results in reducing hypoglycemia, but Tool A's broader impact on preventing general patient deterioration and its compelling outcome data give it a slight edge.

Pricing & Value

Tie

Neither tool provides transparent pricing information, requiring direct contact with the vendor for details. Without specific pricing structures or publicly available, comparable ROI analyses, it is not possible to definitively assess which tool offers better value.

Enterprise Readiness

WAVE Clinical Platform

WAVE Clinical Platform explicitly states its ability to leverage existing hospital IT infrastructure and seamlessly collaborate with Epic applications, a major EMR system. Its acquisition by Hillrom (now Baxter) further indicates strong corporate backing and resources for enterprise-level deployment and support. While EndoTool SubQ is HIPAA compliant and integrates with EMRs, Tool A's explicit EMR integration and corporate backing provide a stronger indication of enterprise readiness.

Innovation

WAVE Clinical Platform

WAVE Clinical Platform stands out as the 'first FDA-cleared AI patient surveillance system,' pioneering the use of predictive algorithms for early detection of general patient deterioration. While EndoTool SubQ's patient-specific insulin dosing with model predictive control is highly innovative, Tool A's foundational role in broad AI-driven patient surveillance represents a slightly greater innovative leap in the healthcare AI space.

Support & Docs

EndoTool SubQ

EndoTool SubQ explicitly outlines comprehensive training as an integral part of its implementation package, including on-site sessions, online modules, and continuous educational support. It also lists various resources like clinical evidence, eBooks, and whitepapers. In contrast, the provided information for WAVE Clinical Platform does not detail specific support or documentation offerings.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	WAVE Clinical Platform	EndoTool SubQ
Tool Name	WAVE Clinical Platform	EndoTool SubQ
Company	Excel Medical Electronics	MONARCH MEDICAL TECHNOLOGIES
Primary Use Case	AI patient surveillance system providing early warning of patient deterioration.	Clinical decision support for any situation where subcutaneous insulin is administered to all patient types, including pediatrics.
Key Technology/Methodology	Predictive algorithms for patient deterioration (e.g., Visensia Safety Index), always-on remote patient monitoring.	Proprietary technology models, predicts and adjusts to each patient's unique physiology and individual response to insulin, model predictive control technology, feedback mathematics.
Specific Patient Focus	Early warning of patient deterioration (up to 6 hours in advance).	Inpatient insulin management for all patient types, including pediatrics.
Integration Capabilities	Integration with Electronic Medical Records (EMR), Mobile device compatibility for alerts and data display.	Not specified

Videos

Demos, reviews, and walkthroughs featuring WAVE Clinical Platform and EndoTool SubQ.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications of each tool?

The WAVE Clinical Platform is an FDA-cleared AI patient surveillance system designed to provide early warning of general patient deterioration. In contrast, EndoTool SubQ provides clinical decision support specifically for subcutaneous insulin administration across all patient types, including pediatrics.

What types of patient data do these tools utilize for their recommendations?

The WAVE Clinical Platform utilizes always-on remote patient monitoring, near real-time physiologic data, waveforms, and alarms for its predictive analytics. EndoTool SubQ considers various patient factors such as blood glucose, height, weight, diabetes type, age, sex, creatinine, steroids, carbohydrate intake, and ordered insulin to provide patient-specific dosing recommendations.

How do the predictive capabilities of these tools differ?

The WAVE Clinical Platform uses predictive algorithms, like the Visensia Safety Index, to offer early warning of patient deterioration up to 6 hours in advance. EndoTool SubQ employs proprietary model predictive control technology and feedback mathematics to model, predict, and adjust to each patient's unique physiological response to insulin.

How do these tools integrate with existing hospital systems and workflows?

The WAVE Clinical Platform integrates with Electronic Medical Records (EMRs) and mobile devices for alerts and data display, and is EMR vendor-agnostic. While not explicitly detailed for EndoTool SubQ, its function of providing insulin dosing recommendations implies interaction with patient data, and it is designed to simplify complex insulin management and integrate seamlessly into hospital processes.

What specific patient safety or outcome improvements can be expected from each tool?

The WAVE Clinical Platform aims to enhance patient safety by predicting preventable deterioration and reducing unexpected deaths in hospitals. EndoTool SubQ focuses on improving inpatient insulin management by providing patient-specific dosing recommendations, reducing and eliminating correctional dosing, promoting mealtime dosing, and recommending supplemental carbohydrates for hypoglycemia prevention.